https://www.selleckchem.com/pr....oducts/z-lehd-fmk-s7
s, within a BMI category, at six months were significantly different (p≤0.01). No difference in the degree of improvement were observed in patients with a BMI ≥ 31. Finally, a multivariate logistic regression analysis indicated that when controlling for BMI, diabetes, a history of cancer, female gender and black and Hispanic race were independently associated with poorer outcomes. CONCLUSIONS Progressive increases in BMI negatively impact CVD related treatment outcomes as measured by rVCSS and CIVIQ 20. Outcomes progressively w
Like
Comment
Share
